On October 13, 2025, Evofem Biosciences, Inc. amended its Securities Purchase Agreement with Adjuvant, changing the maturity date of certain convertible notes to six months after the effective date or upon a change of control. This amendment allows no prepayment of the notes before six months without consent from Adjuvant.